Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CRISPRa-Mediated Upregulation of scn1laa During Early Development Causes Epileptiform Activity and dCas9-Associated Toxicity.

The CRISPR journal - 1 Aug 2021

Weuring Wout J, Dilevska Ivana, Hoekman Jos, van de Vondervoort Joep, Koetsier Martijn, van 't Slot Ruben H, Braun Kees P J, Koeleman Bobby P C

Abstract excerpt

Dravet syndrome (DS) is a monogenic epileptic encephalopathy caused by loss-of-function mutations in the voltage-gated sodium channel (VGSC) gene SCN1A. DS has an age of onset within the first year of life and severe disease prognosis. In the past years, it has been shown that upregulation of endogenous SCN1A can be beneficial in animal models for DS, but a complete rescue was not observed. We hypothesized that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clustered Regularly Interspaced Short Palindromic Repeats
Share to CRISPR-Associated Protein 9

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Embryonic Development

Share to Epilepsies, Myoclonic

Share to Gene Editing

Share to NAV1.1 Voltage-Gated Sodium Channel

Share to RNA, Guide, CRISPR-Cas Systems

Share to Zebrafish Proteins

Source

Identifiers

PMID: 34406040
DOI: 10.1089/crispr.2021.0013

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CRISPRa-Mediated Upregulation of scn1laa During Early Development Causes Epileptiform Activity and dCas9-Associated Toxicity.PMID 34406040Read ↗

CRISPR/dCas9-based Scn1a gene activation in inhibitory neurons ameliorates epileptic and behavioral phenotypes of Dravet syndrome model mice.Semantic proximity Read ↗

AAV delivery of RNA editing machinery rescues SUDEP and seizure phenotype in a mouse model of Dravet SyndromeSemantic proximity Read ↗

NaV1.1 and NaV1.6 selective compounds reduce the behavior phenotype and epileptiform activity in a novel zebrafish model for Dravet Syndrome.Semantic proximity Read ↗

Genetic therapeutic advancements for Dravet Syndrome.Semantic proximity Read ↗

NaV1.1 and NaV1.6 selective compounds reduce the behavior phenotype in a novel zebrafish model for Dravet SyndromeSemantic proximity Read ↗

CRISPR activation for SCN2A-related neurodevelopmental disorders.Semantic proximity Read ↗

New insights into the early mechanisms of epileptogenesis in a zebrafish model of Dravet syndromeSemantic proximity Read ↗

CRISPR-mediated <i>Stxbp1</i> gene activation ameliorates epileptic and aggressive phenotypes in <i>Stxbp1</i> -haploinsufficient miceSemantic proximity Read ↗

PV interneuron-targeted CRISPRa rescue of <i>SCN1A</i> haploinsufficiency in Dravet syndromeSemantic proximity Read ↗

CRISPR activation rescues abnormalities in <i>SCN2A</i> haploinsufficiency-associated autism spectrum disorderSemantic proximity Read ↗

Exogenous Na <sub>V</sub> 1.1 activity in excitatory and inhibitory neurons reverts Dravet syndrome comorbidities when delivered post-symptom onset in mice with DravetSemantic proximity Read ↗

<i>In vivo</i> CRISPRa decreases seizures and rescues cognitive deficits in a rodent model of epilepsySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.